Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages Investors to Contact the Firm

New York, New York, UNITED STATES


NEW YORK, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Ampio Pharmaceuticals, Inc. (AMPE). 

On August 25, 2018, a complaint was filed alleging that defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, defendants’ public statements were materially false and misleading at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages. 

On August 7, 2018, after the market closed, Ampio announced updated business disclosures relating to its AP-003-A and AP-003-C trials, disclosing that the FDA found that, as a single trial, the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a Biologics License Application and that the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial. 

On this news, shares of Ampio fell over 78% to close at $0.61 per share on August 8, 2018. 

If you are a long term stockholder of Ampio, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information concerning our investigation into Ampio Pharmaceuticals, Inc. (AMPE) and Encourages Investors to Contact the Firm please go to https://bespc.com/ampio/.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com